Long-acting injectable CAB-LA safe for HIV PrEP during pregnancy, study finds

Long-acting injectable cabotegravir (CAB-LA) was safe and well tolerated as HIV pre-exposure prophylaxis (PrEP) before and during pregnancy in the follow-up phase of a global study among cisgender women. The analysis of outcomes from more than 300 pregnancies and infants will be presented at the 2024 International AIDS Conference (AIDS 2024) in Munich, Germany. 

Cisgender women experience biological changes and social dynamics that can increase their likelihood of acquiring HIV during pregnancy and the postnatal period, and we need to offer them evidence-based options when they may need them most. These data provide reassurance about long-acting injectable cabotegravir for HIV prevention during pregnancy."

Jeanne Marrazzo, M.D., M.P.H., Director of the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID)

CAB-LA is a highly effective HIV prevention method, administered by intramuscular injection every two months. However, data regarding the safety of CAB-LA during pregnancy are limited. An open-label extension study of the CAB-LA efficacy trial in cisgender women included women in several countries across East and Southern Africa who had the potential to become pregnant during the longitudinal study and who did not have HIV. Participants chose between CAB-LA or oral PrEP with tenofovir disoproxil fumarate and emtricitabine and had the option to use contraception if they wished. They were monitored closely for safety. Participants who became pregnant also were monitored for pregnancy-related adverse events including gestational hypertension, pre-eclampsia, and weight gain, as well as infant outcomes, such as miscarriage, intrauterine fetal death or stillbirth, premature birth, or low birthweight. 

There were 367 pregnancies in this phase of the study. Pregnancy-related maternal adverse event incidence was 45.7, 47.1, and 37.5 per 100 person years among people using CAB-LA during pregnancy, prior to pregnancy, or with no CAB-LA use, respectively. Adverse infant outcomes were similar across groups, with negative outcomes reported in 33%, 38%, and 27% of pregnancies with CAB-LA use, prior CAB-LA use, or no CAB-LA use, respectively. One major congenital anomaly was reported in a participant receiving CAB-LA. No maternal deaths occurred. Pregnancy and infant outcomes in the study were similar to estimated general population outcomes.

Overall, CAB-LA was safe and well tolerated. These findings demonstrate the safety of using CAB-LA prior to and during pregnancy. 

"The overlap between high HIV incidence and the specific risks that cisgender pregnant women face in acquiring HIV in many countries calls for diverse and highly effective PrEP options as part of sexual and reproductive health approaches," said study chair Sinead Delany-Moretlwe, M.B.B.Ch., Ph.D., director of Research at Wits RHI and professor of Global Health and Infectious Diseases at the University of the Witwatersrand, Johannesburg. "We hope that these findings can fill an important knowledge gap that can help increase access to this highly effective HIV PrEP option among cisgender women before, during, and after pregnancy."

This study is conducted and implemented by the NIH-funded HIV Prevention Trials Network (HPTN). NIAID sponsors and co-funds the trial with ViiV Healthcare and the Bill & Melinda Gates Foundation. ViiV Healthcare and Gilead Sciences, Inc., provide study medications. The NIH's National Institute of Mental Health, National Institute on Drug Abuse, and Eunice Kennedy Shriver National Institute of Child Health and Human Development collaborated with NIAID on this study.